Previous 10 | Next 10 |
home / stock / hmtxf / hmtxf news
CALGARY, Alberta, July 11, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company focused on developing and commercializing innovative blood-derived stem cell therapies for medical co...
CALGARY, Alberta, July 02, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company developing and commercializing blood-derived stem cell therapies for unmet medical conditions, is ple...
CALGARY, Alberta, June 27, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to announce that it has enrolled a total of forty (40) patients in its continuing Phase II Clinical Trial for criti...
CALGARY, Alberta, June 25, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company focused on developing and commercializing innovative blood-derived stem cell therapies for medical co...
NOT FOR DISTRIBTUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, May 16, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE: HEM; OTCQB: HMTXF) a biotechnology company focused on ...
NOT FOR DISTRIBTUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, April 15, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE: HEM; OTCQB: HMTXF) a biotechnology company focused o...
CALGARY, Alberta, April 09, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to announce that it has reached an enrollment milestone in its continuing Phase II Clinical Trial for critical lim...
CALGARY, Alberta, April 01, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to announce that Dr. Alan J. Jacobs, M.S.EE, M.D, Ph.D. has been appointed the Company’s President and Chie...
CALGARY, Alberta, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE: HEM; OTCQB:HMTXF) is pleased to announce that it has received all approvals from UC Davis Health (“UC Davis”) located in Sacra...
CALGARY, Alberta, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE: HEM; OTCQB: HMTXF) a biotechnology company focused on developing and commercializing innovative blood-derived stem cell therapies for medical con...
News, Short Squeeze, Breakout and More Instantly...
Calgary, Alberta--(Newsfile Corp. - June 11, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it was notified by the World Intellectual Property Organization that it was granted the trademark Your Fountain of Youth by the Swiss Trademark Office. "In four h...
2024-06-03 13:23:23 ET In a press release this morning, %Hemostemix Inc. (TSXV: $HEM) (OTC: $HMTXF) announced it had signed a Letter of Intent ("LOI") with CytoImmune Therapeutics. The LOI will re-establish production of ACP-01 ("ACP") in CytoImmune's state-of-the-art clinical cell manu...
Calgary, Alberta--(Newsfile Corp. - June 3, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) is pleased to announce it has signed a Letter of Intent ("LOI") with CytoImmune Therapuetics ("CytoImmune") to re-establish production of ACP-01 ("ACP") in CytoImmune's state-of-the-art c...